| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Endophthalmitis | 48 | 2025 | 119 | 18.370 |
Why?
|
| Eye Infections, Bacterial | 53 | 2025 | 122 | 16.360 |
Why?
|
| Bacillus cereus | 22 | 2025 | 58 | 8.860 |
Why?
|
| Gram-Positive Bacterial Infections | 15 | 2025 | 90 | 5.650 |
Why?
|
| Staphylococcus aureus | 21 | 2025 | 115 | 4.130 |
Why?
|
| Mice, Inbred C57BL | 32 | 2025 | 1496 | 3.970 |
Why?
|
| Staphylococcal Infections | 16 | 2025 | 81 | 3.840 |
Why?
|
| Disease Models, Animal | 30 | 2025 | 1405 | 3.290 |
Why?
|
| Bacillus thuringiensis | 6 | 2021 | 19 | 3.210 |
Why?
|
| Retina | 21 | 2025 | 422 | 2.520 |
Why?
|
| Anti-Bacterial Agents | 14 | 2025 | 498 | 2.360 |
Why?
|
| Mice | 35 | 2025 | 4474 | 2.250 |
Why?
|
| Animals | 66 | 2025 | 10085 | 2.230 |
Why?
|
| Toll-Like Receptor 4 | 7 | 2025 | 70 | 2.180 |
Why?
|
| Virulence | 21 | 2023 | 144 | 1.990 |
Why?
|
| Electroretinography | 16 | 2025 | 173 | 1.970 |
Why?
|
| Bacillus | 5 | 2022 | 25 | 1.930 |
Why?
|
| Inflammation | 8 | 2023 | 608 | 1.760 |
Why?
|
| Blood-Retinal Barrier | 5 | 2016 | 27 | 1.720 |
Why?
|
| Chemokine CCL2 | 2 | 2024 | 45 | 1.710 |
Why?
|
| Bacterial Proteins | 11 | 2022 | 474 | 1.560 |
Why?
|
| Bacterial Toxins | 7 | 2019 | 265 | 1.550 |
Why?
|
| Klebsiella Infections | 4 | 2014 | 12 | 1.540 |
Why?
|
| Keratitis | 15 | 2019 | 28 | 1.400 |
Why?
|
| Klebsiella pneumoniae | 6 | 2016 | 28 | 1.360 |
Why?
|
| Immunity, Innate | 4 | 2020 | 212 | 1.310 |
Why?
|
| Neutrophils | 11 | 2021 | 179 | 1.300 |
Why?
|
| Toll-Like Receptor 2 | 6 | 2025 | 29 | 1.250 |
Why?
|
| Uveitis | 4 | 2022 | 23 | 1.250 |
Why?
|
| Membrane Glycoproteins | 2 | 2020 | 143 | 1.240 |
Why?
|
| Colony Count, Microbial | 19 | 2025 | 81 | 1.230 |
Why?
|
| Chemokine CCL3 | 2 | 2024 | 9 | 1.130 |
Why?
|
| Bacillaceae Infections | 5 | 2006 | 7 | 1.120 |
Why?
|
| Rabbits | 26 | 2025 | 275 | 1.070 |
Why?
|
| Leukocidins | 1 | 2025 | 3 | 0.980 |
Why?
|
| Phosphatidylcholines | 2 | 2020 | 41 | 0.880 |
Why?
|
| Cornea | 10 | 2019 | 65 | 0.840 |
Why?
|
| Cytokines | 8 | 2020 | 440 | 0.800 |
Why?
|
| Chemokine CXCL2 | 1 | 2021 | 6 | 0.770 |
Why?
|
| Chemokine CXCL10 | 1 | 2021 | 22 | 0.760 |
Why?
|
| Metalloproteases | 1 | 2021 | 7 | 0.750 |
Why?
|
| Metalloendopeptidases | 1 | 2021 | 39 | 0.740 |
Why?
|
| Fluoroquinolones | 4 | 2013 | 15 | 0.720 |
Why?
|
| Vitreous Body | 7 | 2025 | 22 | 0.700 |
Why?
|
| Retinal Pigment Epithelium | 2 | 2020 | 91 | 0.650 |
Why?
|
| Immunomodulation | 1 | 2019 | 20 | 0.650 |
Why?
|
| Aza Compounds | 3 | 2013 | 11 | 0.640 |
Why?
|
| Quinolines | 3 | 2013 | 25 | 0.640 |
Why?
|
| Bacterial Outer Membrane Proteins | 1 | 2020 | 94 | 0.640 |
Why?
|
| Biomimetic Materials | 1 | 2019 | 20 | 0.640 |
Why?
|
| Glucocorticoids | 4 | 2016 | 114 | 0.620 |
Why?
|
| Peroxidase | 6 | 2024 | 38 | 0.610 |
Why?
|
| Nanostructures | 1 | 2019 | 62 | 0.600 |
Why?
|
| Humans | 28 | 2023 | 27136 | 0.560 |
Why?
|
| Bacteria | 4 | 2013 | 264 | 0.560 |
Why?
|
| Diabetic Retinopathy | 3 | 2016 | 108 | 0.550 |
Why?
|
| Ciprofloxacin | 9 | 2000 | 19 | 0.540 |
Why?
|
| Chemokine CXCL1 | 1 | 2016 | 6 | 0.530 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2016 | 15 | 0.530 |
Why?
|
| Chemokines | 4 | 2020 | 73 | 0.530 |
Why?
|
| Retinal Vessels | 2 | 2016 | 71 | 0.520 |
Why?
|
| Flagella | 2 | 2014 | 27 | 0.520 |
Why?
|
| Anti-Infective Agents | 4 | 2009 | 77 | 0.520 |
Why?
|
| Ophthalmic Solutions | 11 | 2009 | 27 | 0.520 |
Why?
|
| Vitrectomy | 2 | 2016 | 8 | 0.510 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 2015 | 31 | 0.490 |
Why?
|
| Mice, Knockout | 5 | 2024 | 794 | 0.480 |
Why?
|
| Interleukin-6 | 1 | 2016 | 189 | 0.470 |
Why?
|
| Toll-Like Receptor 5 | 1 | 2014 | 5 | 0.460 |
Why?
|
| Drug Therapy, Combination | 6 | 2025 | 205 | 0.450 |
Why?
|
| Male | 12 | 2021 | 13034 | 0.440 |
Why?
|
| Capillary Permeability | 2 | 2012 | 38 | 0.420 |
Why?
|
| Virulence Factors | 4 | 2022 | 45 | 0.410 |
Why?
|
| Chemokines, CXC | 2 | 2023 | 12 | 0.410 |
Why?
|
| Eye | 4 | 2021 | 35 | 0.400 |
Why?
|
| Exotoxins | 3 | 2025 | 6 | 0.400 |
Why?
|
| RNA, Bacterial | 1 | 2011 | 65 | 0.380 |
Why?
|
| Pseudomonas Infections | 8 | 2022 | 24 | 0.380 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2008 | 243 | 0.350 |
Why?
|
| Vancomycin | 5 | 2011 | 56 | 0.340 |
Why?
|
| Host-Pathogen Interactions | 1 | 2010 | 89 | 0.330 |
Why?
|
| Ependymoglial Cells | 2 | 2020 | 29 | 0.330 |
Why?
|
| Flow Cytometry | 4 | 2025 | 285 | 0.330 |
Why?
|
| Cells, Cultured | 4 | 2021 | 977 | 0.330 |
Why?
|
| NF-kappa B | 2 | 2020 | 187 | 0.320 |
Why?
|
| Bacterial Adhesion | 3 | 2020 | 26 | 0.300 |
Why?
|
| Mutation | 3 | 2011 | 819 | 0.300 |
Why?
|
| Polymerase Chain Reaction | 4 | 2018 | 262 | 0.290 |
Why?
|
| Antibodies, Monoclonal | 2 | 2021 | 318 | 0.280 |
Why?
|
| Female | 8 | 2025 | 14650 | 0.280 |
Why?
|
| Genotype | 3 | 2023 | 443 | 0.270 |
Why?
|
| Hemolysin Proteins | 2 | 1999 | 53 | 0.270 |
Why?
|
| Bacterial Physiological Phenomena | 1 | 2007 | 22 | 0.270 |
Why?
|
| Trans-Activators | 3 | 2003 | 114 | 0.270 |
Why?
|
| Dexamethasone | 3 | 2008 | 54 | 0.270 |
Why?
|
| Tobramycin | 4 | 1995 | 13 | 0.260 |
Why?
|
| Pseudomonas aeruginosa | 5 | 2022 | 62 | 0.260 |
Why?
|
| Inflammation Mediators | 3 | 2019 | 153 | 0.260 |
Why?
|
| Retinal Diseases | 1 | 2006 | 45 | 0.260 |
Why?
|
| Gene Expression Regulation, Bacterial | 4 | 2022 | 152 | 0.260 |
Why?
|
| Aqueous Humor | 4 | 2017 | 24 | 0.250 |
Why?
|
| Microbial Sensitivity Tests | 7 | 2008 | 135 | 0.240 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2025 | 110 | 0.220 |
Why?
|
| Treatment Outcome | 2 | 2025 | 2285 | 0.210 |
Why?
|
| Immunohistochemistry | 3 | 2016 | 455 | 0.210 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2019 | 129 | 0.190 |
Why?
|
| Ofloxacin | 2 | 2000 | 4 | 0.180 |
Why?
|
| Preservation, Biological | 1 | 2021 | 11 | 0.180 |
Why?
|
| Intravitreal Injections | 1 | 2021 | 33 | 0.180 |
Why?
|
| Nod2 Signaling Adaptor Protein | 1 | 2020 | 7 | 0.180 |
Why?
|
| Uvea | 1 | 2020 | 2 | 0.180 |
Why?
|
| Th17 Cells | 1 | 2020 | 33 | 0.170 |
Why?
|
| HL-60 Cells | 1 | 2020 | 22 | 0.170 |
Why?
|
| Serpins | 1 | 2020 | 31 | 0.170 |
Why?
|
| Spleen | 1 | 2020 | 109 | 0.170 |
Why?
|
| Diabetes Mellitus, Experimental | 2 | 2012 | 96 | 0.170 |
Why?
|
| Dacryocystitis | 1 | 2019 | 5 | 0.170 |
Why?
|
| Disease Resistance | 1 | 2019 | 18 | 0.160 |
Why?
|
| Phagocytosis | 1 | 2020 | 79 | 0.160 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2019 | 80 | 0.160 |
Why?
|
| Photoreceptor Cells, Vertebrate | 1 | 2020 | 62 | 0.160 |
Why?
|
| Gram-Positive Bacteria | 1 | 1999 | 33 | 0.160 |
Why?
|
| Lymphocyte Activation | 1 | 2020 | 206 | 0.160 |
Why?
|
| Disease Susceptibility | 1 | 2019 | 72 | 0.160 |
Why?
|
| Models, Animal | 1 | 2019 | 129 | 0.160 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2019 | 253 | 0.160 |
Why?
|
| Corneal Ulcer | 3 | 1993 | 12 | 0.160 |
Why?
|
| Erythrocytes | 1 | 2019 | 83 | 0.160 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2019 | 36 | 0.160 |
Why?
|
| Autoimmunity | 1 | 2020 | 154 | 0.160 |
Why?
|
| Nanotechnology | 1 | 2019 | 67 | 0.160 |
Why?
|
| Autoimmune Diseases | 1 | 2020 | 162 | 0.150 |
Why?
|
| T-Lymphocytes | 1 | 2020 | 279 | 0.150 |
Why?
|
| Tight Junctions | 2 | 2009 | 29 | 0.150 |
Why?
|
| Microarray Analysis | 1 | 2018 | 59 | 0.150 |
Why?
|
| Polymers | 1 | 2019 | 114 | 0.150 |
Why?
|
| Analysis of Variance | 1 | 2018 | 388 | 0.140 |
Why?
|
| Mice, Mutant Strains | 1 | 2017 | 58 | 0.140 |
Why?
|
| Collagen | 2 | 1994 | 147 | 0.140 |
Why?
|
| Bacterial Load | 1 | 2016 | 6 | 0.130 |
Why?
|
| Evans Blue | 1 | 2016 | 7 | 0.130 |
Why?
|
| Fluorescein-5-isothiocyanate | 1 | 2016 | 17 | 0.130 |
Why?
|
| Iodates | 1 | 2016 | 10 | 0.130 |
Why?
|
| Dextrans | 1 | 2016 | 22 | 0.130 |
Why?
|
| Methicillin Resistance | 2 | 1994 | 7 | 0.130 |
Why?
|
| Angiography | 1 | 2016 | 35 | 0.130 |
Why?
|
| Coloring Agents | 1 | 2016 | 35 | 0.130 |
Why?
|
| Cefazolin | 2 | 1992 | 6 | 0.130 |
Why?
|
| Gene Expression Profiling | 1 | 2018 | 440 | 0.130 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2015 | 12 | 0.120 |
Why?
|
| DNA, Bacterial | 4 | 2006 | 302 | 0.120 |
Why?
|
| In Vitro Techniques | 3 | 2013 | 240 | 0.120 |
Why?
|
| Chemotactic Factors | 1 | 2014 | 7 | 0.120 |
Why?
|
| Cell Survival | 1 | 2016 | 395 | 0.120 |
Why?
|
| Flagellin | 1 | 2014 | 9 | 0.120 |
Why?
|
| Staphylococcal Protein A | 1 | 1994 | 3 | 0.120 |
Why?
|
| Neutrophil Infiltration | 1 | 2014 | 19 | 0.120 |
Why?
|
| Blotting, Western | 3 | 2014 | 506 | 0.110 |
Why?
|
| Caveolin 1 | 1 | 2014 | 43 | 0.110 |
Why?
|
| Streptococcus pneumoniae | 2 | 2009 | 28 | 0.110 |
Why?
|
| RNA | 1 | 2014 | 105 | 0.110 |
Why?
|
| Phenotype | 2 | 2006 | 668 | 0.110 |
Why?
|
| Eye Infections, Viral | 1 | 1993 | 5 | 0.110 |
Why?
|
| Leukocyte Count | 2 | 2011 | 25 | 0.100 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2011 | 325 | 0.100 |
Why?
|
| Drug Delivery Systems | 1 | 1994 | 216 | 0.100 |
Why?
|
| Antiviral Agents | 1 | 1993 | 111 | 0.100 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2011 | 13 | 0.100 |
Why?
|
| Posterior Eye Segment | 1 | 2011 | 2 | 0.100 |
Why?
|
| Gene Expression Regulation | 1 | 2014 | 626 | 0.090 |
Why?
|
| Preservatives, Pharmaceutical | 2 | 2009 | 4 | 0.090 |
Why?
|
| Benzalkonium Compounds | 2 | 2009 | 9 | 0.090 |
Why?
|
| Combined Modality Therapy | 1 | 2011 | 290 | 0.090 |
Why?
|
| Chemokine CCL20 | 1 | 2010 | 6 | 0.090 |
Why?
|
| Follow-Up Studies | 1 | 2012 | 988 | 0.080 |
Why?
|
| Biological Availability | 2 | 2008 | 43 | 0.080 |
Why?
|
| Staphylococcus epidermidis | 1 | 2009 | 6 | 0.080 |
Why?
|
| Models, Biological | 1 | 2011 | 448 | 0.080 |
Why?
|
| Occludin | 1 | 2009 | 12 | 0.080 |
Why?
|
| Fibrin | 1 | 2009 | 17 | 0.080 |
Why?
|
| Zonula Occludens-1 Protein | 1 | 2009 | 17 | 0.080 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2009 | 50 | 0.080 |
Why?
|
| Serum Albumin | 1 | 2009 | 35 | 0.080 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2009 | 58 | 0.080 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2009 | 39 | 0.080 |
Why?
|
| Time Factors | 2 | 2013 | 1571 | 0.080 |
Why?
|
| Haemophilus influenzae | 1 | 2009 | 66 | 0.080 |
Why?
|
| Phosphoproteins | 1 | 2009 | 116 | 0.080 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 1 | 2008 | 23 | 0.080 |
Why?
|
| Epithelial Cells | 1 | 2010 | 241 | 0.080 |
Why?
|
| Viscosity | 1 | 2008 | 37 | 0.080 |
Why?
|
| Sodium-Potassium-Exchanging ATPase | 1 | 2008 | 10 | 0.070 |
Why?
|
| Severity of Illness Index | 2 | 2008 | 446 | 0.070 |
Why?
|
| Permeability | 1 | 2008 | 59 | 0.070 |
Why?
|
| Bacterial Typing Techniques | 2 | 2006 | 124 | 0.070 |
Why?
|
| Receptor, Insulin | 1 | 2008 | 93 | 0.070 |
Why?
|
| Protein Transport | 1 | 2008 | 153 | 0.070 |
Why?
|
| Toxoplasmosis, Ocular | 1 | 2007 | 2 | 0.070 |
Why?
|
| Antigens, Protozoan | 1 | 2007 | 8 | 0.070 |
Why?
|
| Morbidity | 1 | 2007 | 57 | 0.070 |
Why?
|
| Blindness | 1 | 2007 | 34 | 0.070 |
Why?
|
| Anterior Eye Segment | 1 | 2006 | 4 | 0.070 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2006 | 21 | 0.070 |
Why?
|
| Global Health | 1 | 2007 | 43 | 0.070 |
Why?
|
| Connective Tissue Cells | 1 | 2006 | 1 | 0.070 |
Why?
|
| Peptide Hydrolases | 2 | 1997 | 22 | 0.070 |
Why?
|
| Chemotaxis | 1 | 2006 | 28 | 0.070 |
Why?
|
| Protozoan Proteins | 1 | 2007 | 50 | 0.070 |
Why?
|
| Toxoplasma | 1 | 2007 | 33 | 0.070 |
Why?
|
| Acute Disease | 1 | 2006 | 153 | 0.070 |
Why?
|
| Cell Line | 1 | 2008 | 682 | 0.060 |
Why?
|
| Movement | 1 | 2006 | 95 | 0.060 |
Why?
|
| Membrane Proteins | 1 | 2009 | 467 | 0.060 |
Why?
|
| Prognosis | 1 | 2007 | 763 | 0.060 |
Why?
|
| Postoperative Complications | 1 | 2009 | 605 | 0.060 |
Why?
|
| Base Sequence | 2 | 2002 | 575 | 0.050 |
Why?
|
| Type C Phospholipases | 1 | 2002 | 31 | 0.050 |
Why?
|
| Enterococcus faecalis | 2 | 2007 | 71 | 0.050 |
Why?
|
| Mutagenesis, Insertional | 1 | 2002 | 37 | 0.050 |
Why?
|
| Genes, Bacterial | 1 | 2002 | 106 | 0.050 |
Why?
|
| Epithelium, Corneal | 1 | 2002 | 14 | 0.050 |
Why?
|
| Blood Proteins | 1 | 2002 | 64 | 0.050 |
Why?
|
| Mutagenesis, Site-Directed | 2 | 1999 | 129 | 0.050 |
Why?
|
| Adenosine Triphosphatases | 1 | 2022 | 49 | 0.050 |
Why?
|
| Life Style | 1 | 2022 | 83 | 0.050 |
Why?
|
| Multiprotein Complexes | 1 | 2022 | 53 | 0.050 |
Why?
|
| Receptors, CCR7 | 1 | 2020 | 4 | 0.050 |
Why?
|
| Synovitis | 1 | 2020 | 6 | 0.040 |
Why?
|
| Arthritis | 1 | 2020 | 29 | 0.040 |
Why?
|
| Biofilms | 1 | 2022 | 119 | 0.040 |
Why?
|
| Interleukin-17 | 1 | 2020 | 51 | 0.040 |
Why?
|
| Carrier Proteins | 1 | 2002 | 246 | 0.040 |
Why?
|
| Sarcoidosis | 1 | 2020 | 38 | 0.040 |
Why?
|
| Eye Proteins | 1 | 2002 | 197 | 0.040 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2020 | 102 | 0.040 |
Why?
|
| Herpesvirus 1, Human | 1 | 2019 | 24 | 0.040 |
Why?
|
| Organ Specificity | 1 | 2019 | 81 | 0.040 |
Why?
|
| Mice, Transgenic | 1 | 2020 | 489 | 0.040 |
Why?
|
| DNA-Binding Proteins | 1 | 2022 | 481 | 0.040 |
Why?
|
| Corneal Stroma | 2 | 1997 | 6 | 0.040 |
Why?
|
| Prednisolone | 2 | 1995 | 6 | 0.030 |
Why?
|
| Transcription Factors | 2 | 1997 | 512 | 0.030 |
Why?
|
| ADP Ribose Transferases | 1 | 1996 | 4 | 0.030 |
Why?
|
| Tears | 1 | 1996 | 10 | 0.030 |
Why?
|
| Biomarkers | 1 | 2019 | 738 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 2 | 2008 | 66 | 0.030 |
Why?
|
| Random Allocation | 2 | 1993 | 148 | 0.030 |
Why?
|
| Pneumococcal Infections | 1 | 1995 | 23 | 0.030 |
Why?
|
| Administration, Topical | 1 | 1994 | 28 | 0.030 |
Why?
|
| Iontophoresis | 1 | 1994 | 3 | 0.030 |
Why?
|
| Drug Resistance, Microbial | 1 | 1994 | 34 | 0.030 |
Why?
|
| Leukocytes | 1 | 2014 | 68 | 0.030 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 1994 | 73 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 1994 | 218 | 0.030 |
Why?
|
| Leukopenia | 1 | 1993 | 5 | 0.030 |
Why?
|
| Drug Carriers | 1 | 1994 | 110 | 0.030 |
Why?
|
| Injections, Intraocular | 1 | 2013 | 5 | 0.030 |
Why?
|
| Equipment Contamination | 1 | 2013 | 7 | 0.030 |
Why?
|
| Conjunctiva | 1 | 2013 | 14 | 0.030 |
Why?
|
| Keratitis, Herpetic | 1 | 1993 | 4 | 0.030 |
Why?
|
| Needles | 1 | 2013 | 26 | 0.030 |
Why?
|
| Biological Assay | 1 | 1993 | 34 | 0.030 |
Why?
|
| Virus Replication | 1 | 1993 | 63 | 0.030 |
Why?
|
| DNA Fingerprinting | 2 | 2001 | 7 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2008 | 165 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2008 | 229 | 0.020 |
Why?
|
| Amino Acid Sequence | 2 | 2002 | 679 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2008 | 568 | 0.020 |
Why?
|
| Plasmids | 2 | 1998 | 122 | 0.020 |
Why?
|
| Histocytochemistry | 1 | 2007 | 20 | 0.020 |
Why?
|
| Propionibacterium acnes | 1 | 2007 | 1 | 0.020 |
Why?
|
| Molecular Sequence Data | 2 | 2002 | 1041 | 0.020 |
Why?
|
| Microscopy | 1 | 2007 | 38 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2007 | 116 | 0.020 |
Why?
|
| Liver | 1 | 2008 | 424 | 0.020 |
Why?
|
| Monocyte Chemoattractant Proteins | 1 | 2002 | 4 | 0.010 |
Why?
|
| Interleukin-1 | 1 | 2002 | 23 | 0.010 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2002 | 58 | 0.010 |
Why?
|
| Antimicrobial Cationic Peptides | 1 | 2002 | 32 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 2002 | 205 | 0.010 |
Why?
|
| Fibroblasts | 1 | 2002 | 153 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2002 | 241 | 0.010 |
Why?
|
| Bacterial Capsules | 1 | 2001 | 8 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2002 | 408 | 0.010 |
Why?
|
| Phylogeny | 1 | 2001 | 462 | 0.010 |
Why?
|
| Molecular Epidemiology | 1 | 1998 | 4 | 0.010 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 1 | 1998 | 6 | 0.010 |
Why?
|
| Cytotoxins | 1 | 1998 | 51 | 0.010 |
Why?
|
| Genome, Bacterial | 1 | 1998 | 68 | 0.010 |
Why?
|
| Iritis | 1 | 1997 | 1 | 0.010 |
Why?
|
| Scleritis | 1 | 1997 | 1 | 0.010 |
Why?
|
| Genetic Complementation Test | 1 | 1997 | 24 | 0.010 |
Why?
|
| Corneal Diseases | 1 | 1997 | 21 | 0.010 |
Why?
|
| Sclera | 1 | 1997 | 11 | 0.010 |
Why?
|
| Edema | 1 | 1997 | 18 | 0.010 |
Why?
|
| Epithelium | 1 | 1997 | 39 | 0.010 |
Why?
|
| Species Specificity | 1 | 1997 | 187 | 0.010 |
Why?
|
| Recombination, Genetic | 1 | 1997 | 62 | 0.010 |
Why?
|
| Serine Endopeptidases | 1 | 1996 | 18 | 0.010 |
Why?
|
| Edetic Acid | 1 | 1996 | 5 | 0.010 |
Why?
|
| Norfloxacin | 1 | 1996 | 4 | 0.010 |
Why?
|
| Gene Expression | 1 | 1998 | 408 | 0.010 |
Why?
|
| Chelating Agents | 1 | 1996 | 22 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1996 | 128 | 0.010 |
Why?
|
| Streptolysins | 1 | 1995 | 18 | 0.010 |
Why?
|
| Complement Activation | 1 | 1995 | 25 | 0.010 |
Why?
|
| Immunocompromised Host | 1 | 1993 | 26 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 1993 | 509 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 1993 | 751 | 0.010 |
Why?
|